Showing results (21-30 of 673) with videos related to

Sort By:
Pageof 68
HIV Clinical Trials|November 18, 2018
Bone mass preservation with high-dose cholecalciferol and dietary calcium in HIV patients following antiretroviral therapy. Is it possible?Quirico Mela, Valeria Ruggiero, Lorenza Montaldo, et al.
HIV Clinical Trials|November 18, 2018
Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trialMiranda I Murray, Martin Markowitz, Ian Frank, et al.
HIV Clinical Trials|November 20, 2018
Sleep and neuropsychological performance in HIV+ subjects on efavirenz-based therapy and response to switch in therapyCecilia M Shikuma, Lindsay Kohorn, Robert Paul, et al.
HIV Clinical Trials|November 14, 2018
Red blood cell distribution width as an easily measurable biomarker of persistent inflammation and T cell dysregulation in antiretrovirally treated HIV-infected adultsZao Zhang, Glen M Chew, Cecilia M Shikuma, et al.
HIV Clinical Trials|March 21, 2019
Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trialRisa M Hoffman, Konstantia Nadia Angelidou, Sean S Brummel, et al.
HIV Clinical Trials|March 21, 2019
Participant characteristics and clinical trial decision-making factors in AIDS malignancy consortium treatment trials for HIV-infected persons with cancer (AMC #S006)Jack E Burkhalter, David M Aboulafia, Maria Botello-Harbaum, et al.
HIV Clinical Trials|April 19, 2012
Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissueS M E Vrouenraets, F W N M Wit, E Fernandez Garcia, et al.
HIV Clinical Trials|February 7, 2012
High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adultsCurtis Cooper, Marina Klein, Sharon Walmsley, et al.
HIV Clinical Trials|February 7, 2012
The dose-response relationship of peginterferon alfa-2a and ribavirin in the treatment of patients coinfected with HIV-HCVMilos Opravil, Maribel Rodriguez-Torres, Jürgen Rockstroh, et al.
HIV Clinical Trials|June 21, 2011
Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patientsDaniel J Skiest, Calvin Cohen, Karam Mounzer, et al.
Pageof 68